Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00547261 · ClinicalTrials.gov registry record · Phase 1
Phase I Dose Finding Study of SSR97225 Given in Patients With Refractory Cancer
A Phase 1 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT00547261: Clinical Trial Phase 1 study, sponsored by Sanofi.
NCT00547261 is a Phase 1 study that was terminated before completion, run by Sanofi. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00547261, a Phase 1 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the maximally tolerated dose and the dose limiting toxicity of this antimitotic, tubulin binding investigational drug for those patients who have failed standard anticancer treatments.
Interventions
- DRUG SSR97225
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2007-10 |
| Est. Completion | 2008-08 |
| Phase | Phase 1 |
Why NCT00547261 stopped before completion
NCT00547261 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which SSR97225 is the first listed.
NCT00547261 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00547261 about?
NCT00547261 is a clinical study titled "Phase I Dose Finding Study of SSR97225 Given in Patients With Refractory Cancer". The purpose of this study is to determine the maximally tolerated dose and the dose limiting toxicity of this antimitotic, tubulin binding investigational drug for those patients who have failed standard anticancer treatments.
What is the current status of trial NCT00547261?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2007-10. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00547261?
The interventions under investigation include: SSR97225 (DRUG).
Who is sponsoring clinical trial NCT00547261?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00547261's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia